SCANA Corporation : Below the upper bound
Entry price | Target | Stop-loss | Potential |
---|
US$39.54 |
US$36.2 |
US$41.1 |
+8.44% |
---|
The zone, in which the stock price is currently trading and which forms a technical resistance, paves the way for a pullback of the stock over the coming trading sessions towards 37.13 USD.
Summary● In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
● The company has poor fundamentals for a short-term investment strategy.
Strengths● This company will be of major interest to investors in search of a high dividend stock.
Weaknesses● The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
● As estimated by analysts, this group is among those businesses with the lowest growth prospects.
● One of the major weak points of the company is its financial situation.
● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
● Revenue estimates are regularly revised downwards for the current and coming years.
● For the last few months, analysts have been revising downwards their earnings forecast.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.